Nexalin Seeks Shareholder Approval for Reverse Split, Equity Plan, and Preferred Stock to Avoid Nasdaq Delisting

summarizeSummary

Nexalin Technology's definitive proxy seeks approval for a reverse stock split to maintain its Nasdaq listing, a new equity plan, and preferred stock authorization — critical governance moves for a company with a going-concern warning and a sub-$1 stock price.

check_boxKey Events · Corporate Governance and Compliance · NXL

• Reverse Stock Split Proposed

  To regain compliance with Nasdaq's $1.00 minimum bid price, the board seeks approval for a reverse split at a ratio between 1-for-2 and 1-for-100, with the aggregate not exceeding 1-for-250. The stock closed at $0.35 on the record date.

• 2026 Equity Incentive Plan

  A new plan is proposed with 7,000,000 shares (approximately 32% of current outstanding), replacing the 2023 Plan. Contingent option grants of 2.4 million shares to executives and directors hinge on approval.

• Blank-Check Preferred Stock Authorization

  Authorization is sought for 10 million shares of preferred stock with terms to be set by the board, potentially enabling anti-takeover measures or future financings without further shareholder votes.

• Officer Exculpation Amendment

  This proposal would extend liability protections to officers for duty of care breaches, aligning with recent Delaware law changes, which could reduce accountability for management decisions.

auto_awesomeAnalysis · NXL · Industrial Applications And Services

To preserve its Nasdaq listing, Nexalin Technology is asking shareholders to approve a reverse stock split, a new 7-million-share equity incentive plan, and 10 million shares of blank-check preferred stock. The company is burning cash, carries a going-concern warning, and its stock trades at $0.45 — well below the $1.00 minimum bid requirement. While the reverse split is a survival move to avoid delisting, the equity plan and preferred stock authorization equip management with tools to raise capital or defend against takeovers, potentially diluting existing holders. The proxy also includes officer exculpation and auditor ratification. The meeting is set for August 11, 2026.